Intangible Assets

AbbVie's Humira-era franchise and current immunology portfolio (Skyrizi and Rinvoq) reflect durable patent-backed exclusivity that supports pricing power better than most large-cap pharma peers, although eventual LOE risk keeps it below structural-dominance levels.

The company’s branded specialty-drug mix is harder to replicate than diversified pharma peers with broader generic exposure, because clinical differentiation and regulatory barriers slow substitution in core indications.

AbbVie’s pipeline and lifecycle management are meaningful moat reinforcers, but they are less durable than the strongest peer moats because patent protection is time-bound and competitors can eventually launch differentiated alternatives.

Compared with peers such as Pfizer and Bristol Myers Squibb, AbbVie’s intangible assets are more concentrated in a few high-value assets, which strengthens near- to medium-term pricing power but increases long-run concentration risk.

Switching Costs

In immunology and specialty care, physicians and payers face clinical and formulary inertia once a therapy is established, which supports retention better than in commoditized primary-care drugs.

AbbVie’s therapies can become embedded in treatment pathways, but switching costs are lower than in platform-like healthcare businesses because payers can still force step edits, prior authorization, or preferred-product shifts.

Relative to peers, AbbVie benefits from stronger persistence in chronic specialty indications than companies with more acute-care or hospital-dependent portfolios, but it does not create the kind of patient or provider lock-in seen in truly indispensable platforms.

The company’s switching-cost advantage is durable enough to protect margins over a 5–10 year window, yet it remains vulnerable to biosimilar competition and payer-driven substitution.

Network Effects

AbbVie does not operate a meaningful network-effect business because demand for its drugs does not become more valuable as more users join the platform.

Clinical adoption can create reference momentum among physicians, but that is not a self-reinforcing network effect and is weaker than the ecosystem effects seen in software or marketplaces.

Compared with peers, AbbVie has no material data, user, or developer network that compounds competitive advantage over time.

Any commercial scale benefits come from sales execution and portfolio breadth rather than network-driven lock-in, so this moat source is effectively absent.

Cost Advantage

AbbVie’s scale in R&D, manufacturing, and global commercialization lowers unit costs versus smaller biotech peers, but it does not create a decisive cost edge versus other large pharma companies.

The company can spread fixed development and regulatory costs across a large revenue base, which supports margins, yet peers like Merck, J&J, and Pfizer also possess similar scale economics.

Specialty-drug pricing power matters more than low production cost in AbbVie’s model, so cost advantage is secondary to patent and clinical differentiation.

Compared with peers, AbbVie’s cost structure is competitive but not structurally superior enough to be a primary moat driver.

Efficient Scale

AbbVie participates in therapeutic areas where the number of credible large-scale competitors is limited by high clinical, regulatory, and capital requirements, which helps preserve industry economics.

The company’s scale in immunology and aesthetics supports efficient commercialization, but the market is not so small that competition is eliminated, so the advantage is meaningful rather than exclusive.

Relative to peers, AbbVie is better positioned than smaller biotech firms because it can fund late-stage development and global launches, but it is less insulated than companies with monopoly-like franchise positions.

Efficient scale is strongest where AbbVie’s established franchises deter undercapitalized entrants, yet biosimilars and large pharma rivals still cap the durability of this advantage.

Overall Score

AbbVie has a strong but not dominant moat, led by patent-backed intangible assets, durable specialty-drug switching costs, and efficient scale in high-barrier therapeutic areas, while the absence of network effects and only moderate cost advantage keep it below exceptional structural-dominance territory versus large pharma peers.